Search results
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Motley Fool via Yahoo Finance· 4 days agoThat's a nice spot to be in, which makes Eli Lilly a likely dividend superstar moving forward. 3. ...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript May 9, 2024 Ironwood ...
Agios Pharmaceuticals, Inc. to Post Q2 2025 Earnings of ($1.62) Per Share, Zacks Research Forecasts...
ETF DAILY NEWS· 7 days agoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities researchers at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Agios
Truist Financial Reiterates “Buy” Rating for Amneal Pharmaceuticals (NASDAQ:AMRX)
ETF DAILY NEWS· 7 days agoAmneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Truist Financial in a research report issued on Monday ...
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Zacks· 6 days agoFree Report) reported first-quarter 2024 adjusted earnings of 48 cents per share, which missed the Zacks Consensus Estimate of 51 cents per share. Earnings rose 20% year over year on a reported ...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters· 5 days ago, opens new tab blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. In the wake of February's U.S. Food and Drug Administration ...
Canaccord Genuity Group Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $109.00
ETF DAILY NEWS· 7 days agoUltragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its target price lowered by equities research analysts at Canaccord Genuity Group from $111.00 to $109.00 in ...
Recursion Pharmaceuticals (RXRX) Scheduled to Post Quarterly Earnings on Thursday
ETF DAILY NEWS· 7 days agoRecursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Recursion
Hikma Pharmaceuticals (LON:HIK) Receives “Equal Weight” Rating from Barclays
ETF DAILY NEWS· 7 days agoBarclays reiterated their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports ...
2nd Circuit Clarifies When ‘Pay-for-Delay’ Deals Are Legal in Tossing Antitrust Claims | Law.com
Law.com· 10 hours agoThe U.S. Court of Appeals for the Second Circuit on Monday upheld the dismissal of a lawsuit...